Loading organization details...
Loading organization details...
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2024
Total Revenue
▼$7.5M
Program Spending
74%
of total expenses go to program services
Total Contributions
$500K
Total Expenses
▼$17.5M
Total Assets
$204.5M
Total Liabilities
▼$5.4M
Net Assets
$199.1M
Officer Compensation
→$806.9K
Other Salaries
$6.1M
Investment Income
$6.9M
Fundraising
▼N/A
Source: USAspending.gov · Searched by organization name
Total Federal Funding
$1.1M
Awards Found
3
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| Department of Health and Human Services | DE NOVO DESIGN OF GENERALIZABLE ALLOSTERIC MODULATORS AND PEPTIDE LIGANDS FOR G PROTEIN COUPLED RECEPTORS | $412.5K | FY2020 | May 2020 – Jan 2022 |
| National Science Foundation | CRCNS US-GERMAN RESEARCH PROPOSAL: COMBINING COMPUTATIONAL MODELING AND ARTIFICIAL INTELLIGENCE TO UNDERSTAND RECEPTOR FUNCTION IN PHYSIOLOGY AND DISEASE | $409.2K | FY2022 | Jan 2022 – Dec 2024 |
| Department of Health and Human Services | COMPUTATIONAL DE NOVO DESIGN OF A DISULFIDE-RICH MINIPROTEIN SYNTHETIC LIBRARY AND ITS APPLICATION TO ENGINEER BINDERS TO NEUTRALIZING EPITOPES ON CLOSTRIDIUM DIFFICILE TOXINS TCDA AND TCDB - PROJECT SUMMARY DISULFIDE-RICH MINIPROTEINS ARE A POWERFUL YET UNDERUTILIZED PROTEIN FAMILY FOR REAGENT, DIAGNOSTIC AND THERAPEUTIC APPLICATIONS. THEY ARE HYPERSTABLE LIKE SMALL MOLECULES, YET ARE LARGE ENOUGH TO BIND SPECIFICALLY TO PROTEIN TARGETS WITH HIGH AFFINITY AND THUS CAN BE READILY USED TO INHIBIT PROTEIN-PROTEIN INTERACTIONS. DISULFIDE-RICH MINIPROTEINS OCCUR NATURALLY, BUT THE NATURAL MOLECULES ARE CHALLENGING TO ENGINEER. THERE IS A PRESSING NEED FOR NEW TECHNOLOGIES WHICH ENABLE DISULFIDE-RICH MINIPROTEINS TO BE ENGINEERED TO BIND TO ARBITRARY PROTEIN TARGETS, AS IS ROUTINE FOR OTHER PROTEIN SCAFFOLDS LIKE ANTIBODIES. HERE, WE PROPOSE A COMPUTATIONAL DE NOVO DESIGN STRATEGY USING ROSETTA TO BUILD A SYNTHETIC MINIPROTEIN LIBRARY THAT WILL BE GENERALLY USEFUL FOR SCREENING PROTEIN AFFINITY REAGENTS. THE TYPICAL APPROACH TO CREATING PROTEIN LIBRARIES IS TO GENERATE A LARGE AMOUNT OF RANDOM SEQUENCE DIVERSITY IN A LOCALIZED AREA OF A SINGLE PROTEIN STRUCTURE. MOST OF THESE SEQUENCES WILL BE UNSTABLE OR UNABLE TO BIND ANY TARGET (E.G. TOO POLAR OR TOO NONPOLAR). RATHER THAN USE RANDOM SEQUENCES, WE PROPOSE TO EXPLICITLY DESIGN EACH MEMBER OF A SYNTHETIC DISULFIDE-RICH MINIPROTEIN LIBRARY. OUR DESIGN LIBRARY WILL CONTAIN 106 DIFFERENT MINIPROTEINS THAT DISPLAY THE WIDEST POSSIBLE VARIETY OF BINDING SURFACES. THE GENES ENCODING THIS LIBRARY WILL BE SYNTHESIZED USING OLIGO POOLS. TO PERFORM COMPUTATIONAL DE NOVO DESIGN AT THIS SCALE, WE EXTENDED THE SEWING ALGORITHM IN ROSETTA TO GENERATE HUNDREDS OF THOUSANDS OF UNIQUE MINIPROTEIN STRUCTURES AND SEQUENCES. WE DEVELOPED NOVEL FILTERS TO ASSESS DESIGN MODEL QUALITY AND TO QUANTIFY AND COMPARE PROTEIN STRUCTURES AND SURFACES. AS A TEST CASE OF THIS APPROACH, WE WILL SCREEN OUR DISULFIDE-RICH MINIPROTEIN LIBRARY VIA YEAST DISPLAY FOR BINDERS TO CLOSTRIDIUM DIFFICILE ENTEROTOXINS TCDA AND TCDB. C. DIFFICILE IS THE LEADING CAUSE OF HEALTHCARE-RELATED INFECTIONS IN THE USA, AND THESE TWO PROTEINS MEDIATE ITS PATHOGENICITY. AT PRESENT, THE ONLY AVAILABLE TREATMENTS FOR C. DIFFICILE ENTERIC INFECTION THAT TARGET THESE TOXIN PROTEINS ARE ANTIBODIES, WHICH MUST BE INJECTED AND HAVE POOR EFFICACY. A HYPERSTABLE MINIPROTEIN BINDER TO THE SAME NEUTRALIZING EPITOPE COULD BE ADMINISTERED ORALLY. THEREFORE, THIS WORK PRESENTS A NEW FRONTIER IN DE NOVO MINIPROTEIN ENGINEERING AND LIBRARY DESIGN. IT WILL ALSO RESULT IN A SOURCE OF NOVEL, THERAPEUTICALLY INTERESTING MOLECULES FOR THE TREATMENT OF C. DIFFICILE INFECTION. | $246.3K | FY2021 | Dec 2020 – Dec 2021 |
Department of Health and Human Services
$412.5K
DE NOVO DESIGN OF GENERALIZABLE ALLOSTERIC MODULATORS AND PEPTIDE LIGANDS FOR G PROTEIN COUPLED RECEPTORS
National Science Foundation
$409.2K
CRCNS US-GERMAN RESEARCH PROPOSAL: COMBINING COMPUTATIONAL MODELING AND ARTIFICIAL INTELLIGENCE TO UNDERSTAND RECEPTOR FUNCTION IN PHYSIOLOGY AND DISEASE
Department of Health and Human Services
$246.3K
COMPUTATIONAL DE NOVO DESIGN OF A DISULFIDE-RICH MINIPROTEIN SYNTHETIC LIBRARY AND ITS APPLICATION TO ENGINEER BINDERS TO NEUTRALIZING EPITOPES ON CLOSTRIDIUM DIFFICILE TOXINS TCDA AND TCDB - PROJECT SUMMARY DISULFIDE-RICH MINIPROTEINS ARE A POWERFUL YET UNDERUTILIZED PROTEIN FAMILY FOR REAGENT, DIAGNOSTIC AND THERAPEUTIC APPLICATIONS. THEY ARE HYPERSTABLE LIKE SMALL MOLECULES, YET ARE LARGE ENOUGH TO BIND SPECIFICALLY TO PROTEIN TARGETS WITH HIGH AFFINITY AND THUS CAN BE READILY USED TO INHIBIT PROTEIN-PROTEIN INTERACTIONS. DISULFIDE-RICH MINIPROTEINS OCCUR NATURALLY, BUT THE NATURAL MOLECULES ARE CHALLENGING TO ENGINEER. THERE IS A PRESSING NEED FOR NEW TECHNOLOGIES WHICH ENABLE DISULFIDE-RICH MINIPROTEINS TO BE ENGINEERED TO BIND TO ARBITRARY PROTEIN TARGETS, AS IS ROUTINE FOR OTHER PROTEIN SCAFFOLDS LIKE ANTIBODIES. HERE, WE PROPOSE A COMPUTATIONAL DE NOVO DESIGN STRATEGY USING ROSETTA TO BUILD A SYNTHETIC MINIPROTEIN LIBRARY THAT WILL BE GENERALLY USEFUL FOR SCREENING PROTEIN AFFINITY REAGENTS. THE TYPICAL APPROACH TO CREATING PROTEIN LIBRARIES IS TO GENERATE A LARGE AMOUNT OF RANDOM SEQUENCE DIVERSITY IN A LOCALIZED AREA OF A SINGLE PROTEIN STRUCTURE. MOST OF THESE SEQUENCES WILL BE UNSTABLE OR UNABLE TO BIND ANY TARGET (E.G. TOO POLAR OR TOO NONPOLAR). RATHER THAN USE RANDOM SEQUENCES, WE PROPOSE TO EXPLICITLY DESIGN EACH MEMBER OF A SYNTHETIC DISULFIDE-RICH MINIPROTEIN LIBRARY. OUR DESIGN LIBRARY WILL CONTAIN 106 DIFFERENT MINIPROTEINS THAT DISPLAY THE WIDEST POSSIBLE VARIETY OF BINDING SURFACES. THE GENES ENCODING THIS LIBRARY WILL BE SYNTHESIZED USING OLIGO POOLS. TO PERFORM COMPUTATIONAL DE NOVO DESIGN AT THIS SCALE, WE EXTENDED THE SEWING ALGORITHM IN ROSETTA TO GENERATE HUNDREDS OF THOUSANDS OF UNIQUE MINIPROTEIN STRUCTURES AND SEQUENCES. WE DEVELOPED NOVEL FILTERS TO ASSESS DESIGN MODEL QUALITY AND TO QUANTIFY AND COMPARE PROTEIN STRUCTURES AND SURFACES. AS A TEST CASE OF THIS APPROACH, WE WILL SCREEN OUR DISULFIDE-RICH MINIPROTEIN LIBRARY VIA YEAST DISPLAY FOR BINDERS TO CLOSTRIDIUM DIFFICILE ENTEROTOXINS TCDA AND TCDB. C. DIFFICILE IS THE LEADING CAUSE OF HEALTHCARE-RELATED INFECTIONS IN THE USA, AND THESE TWO PROTEINS MEDIATE ITS PATHOGENICITY. AT PRESENT, THE ONLY AVAILABLE TREATMENTS FOR C. DIFFICILE ENTERIC INFECTION THAT TARGET THESE TOXIN PROTEINS ARE ANTIBODIES, WHICH MUST BE INJECTED AND HAVE POOR EFFICACY. A HYPERSTABLE MINIPROTEIN BINDER TO THE SAME NEUTRALIZING EPITOPE COULD BE ADMINISTERED ORALLY. THEREFORE, THIS WORK PRESENTS A NEW FRONTIER IN DE NOVO MINIPROTEIN ENGINEERING AND LIBRARY DESIGN. IT WILL ALSO RESULT IN A SOURCE OF NOVEL, THERAPEUTICALLY INTERESTING MOLECULES FOR THE TREATMENT OF C. DIFFICILE INFECTION.
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Tax Year 2025 · Source: IRS e-Filed Form 990
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2024IRS e-File | $7.5M | $500K | $17.5M | $204.5M | $199.1M |
| 2023 | $4M | $235.6K | $13.2M | $196.8M | $191.2M |
| 2022 | $5.2M | $206.7K | $11M | $191M | $189.9M |
| 2021 | $200.8M | $195.2M | $9.3M |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2025 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2024 | 990 | DataIRS e-File | |
| 2023 | 990 | DataIRS e-File |
Financial data: IRS e-Filed Form 990 (Tax Year 2024)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2025)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Kenneth Fasman | President & Ceo/ex-officio | 40 | $698.2K | $0 | $110.9K | $809K |
| Bettina Stevens | CFO (until 10/24) | 40 | $248.2K | $0 | $46K | $294.2K |
| Michael O'Hara | Treasurer | 1 | $0 | $0 | $0 | $0 |
| Samantha Singer | Chair | 1 | $0 | $0 | $0 | $0 |
Kenneth Fasman
President & Ceo/ex-officio
$809K
Hrs/Wk
40
Compensation
$698.2K
Related Orgs
$0
Other
$110.9K
Bettina Stevens
CFO (until 10/24)
$294.2K
Hrs/Wk
40
Compensation
$248.2K
Related Orgs
$0
Other
$46K
Michael O'Hara
Treasurer
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Samantha Singer
Chair
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Rob Meijers | Senior Director Antibody Platform | 40 | $278K | $0 | $52.3K | $330.3K |
| Trisha Gura | Dir. Of Communications | 40 | $239.7K | $0 | $44.3K | $284K |
| Andre Teixeira | Sr. Dir. Of Antibody Platform | 40 | $238.3K | $0 | $45.1K | $283.3K |
| Deborah Moshinsky | Director Antibody Characterization | 40 | $237.6K | $0 | $42.8K | $280.4K |
| Curtis Walton | Director Of Laboratory Automation | 40 | $233.3K | $0 | $44.2K | $277.5K |
Rob Meijers
Senior Director Antibody Platform
$330.3K
Hrs/Wk
40
Compensation
$278K
Related Orgs
$0
Other
$52.3K
Trisha Gura
Dir. Of Communications
$284K
Hrs/Wk
40
Compensation
$239.7K
Related Orgs
$0
Other
$44.3K
Andre Teixeira
Sr. Dir. Of Antibody Platform
$283.3K
Hrs/Wk
40
Compensation
$238.3K
Related Orgs
$0
Other
$45.1K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Dr Amir Nashat | Director | 1 | $0 | $0 | $0 | $0 |
| Dr Auro Nair | Director | 1 | $0 | $0 | $0 | $0 |
| Dr Jeffrey Flier | Director (until 12/24) | 1 | $0 | $0 | $0 | $0 |
| Dr Maykin Ho | Director | 1 | $0 | $0 | $0 | $0 |
| Dr Rusty Williams | Director | 1 | $0 | $0 | $0 | $0 |
| Dr Stephen Blacklow | Director |
Dr Amir Nashat
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Dr Auro Nair
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Dr Jeffrey Flier
Director (until 12/24)
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
| $219.1M |
| $218M |
| 2020 | $24.7M | $24.1M | $7.6M | $26.6M | $25.5M |
| 2019 | $1.5M | $736.2K | $7.1M | $9.2M | $8.5M |
| 2018 | $8.8M | $8.7M | $3.9M | $15.4M | $13.9M |
| 2017 | $10.1M | $11M | $532.2K | $9.8M | $9.6M |
| 2022 | 990 | DataIRS e-File |
| 2021 | 990 | Data |
| 2020 | 990 | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
Deborah Moshinsky
Director Antibody Characterization
$280.4K
Hrs/Wk
40
Compensation
$237.6K
Related Orgs
$0
Other
$42.8K
Curtis Walton
Director Of Laboratory Automation
$277.5K
Hrs/Wk
40
Compensation
$233.3K
Related Orgs
$0
Other
$44.2K
| 1 |
| $0 |
| $0 |
| $0 |
| $0 |
| Dr Steven C Almo | Director | 1 | $0 | $0 | $0 | $0 |
| Dr Timothy A Springer | Co-founder/director | 1 | $0 | $0 | $0 | $0 |
| Israel Rozen | Director | 1 | $0 | $0 | $0 | $0 |
Dr Maykin Ho
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Dr Rusty Williams
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Dr Stephen Blacklow
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Dr Steven C Almo
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Dr Timothy A Springer
Co-founder/director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Israel Rozen
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0